Status:
COMPLETED
COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias
Lead Sponsor:
French Innovative Leukemia Organisation
Collaborating Sponsors:
French Intergroup of Myeloproliferative syndromes
Conditions:
Myeloproliferative Neoplasm
COVID-19 Infection
Eligibility:
All Genders
18+ years
Brief Summary
The classic myeloproliferative neoplasias (MNP), including polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) or secondary to PV or ET, are among the most frequent of ...
Detailed Description
It is a descriptive, prospective epidemiological study using retrospective patient data, multicenter, non-interventional, carried out in FIM (French Intergroup of Myeloproliferative syndromes) / FILO ...
Eligibility Criteria
Inclusion
- Patient with PV, ET, PMF or MF secondary to PV or ET diagnosed before the COVID-19 pandemic
- Seen in consultation or teleconsultation from May 2020 or deceased if the investigator became aware of this death during the study period
Exclusion
- Refusal to participate in the study
Key Trial Info
Start Date :
May 18 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2022
Estimated Enrollment :
1793 Patients enrolled
Trial Details
Trial ID
NCT04416438
Start Date
May 18 2020
End Date
September 1 2022
Last Update
October 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Paris Saint Louis
Paris, France, 75475